Mjoli N, Le Feuvre D, Taylor A
Department Neurosurgery, University of Cape Town, Cape Town, South Africa.
Interv Neuroradiol. 2011 Sep;17(3):323-30. doi: 10.1177/159101991101700307. Epub 2011 Oct 17.
Arteriovenous malformation (AVM) patients who initially present with intracerebral haemorrhage may have an identifiable source of bleeding on angiogram, which can be a treatment target. Previous work suggests that the re-bleed rate may be lowered if a weak area is eliminated.A retrospective cohort study was conducted on patients who presented over a six-year period with a bled AVM. Cases were reviewed looking for the source of the hemorrhage by correlating haematoma location on CT or MRI and any angio-architectural weakness seen on digital subtraction angiography (DSA). Neuroendovascular notes were reviewed to identify the treatment targets. One hundred patients presented with a brain AVM with a 1.7:1 male: female ratio, 41 patients had an initial presentation of hemorrhage. The source of hemorrhage was identified in 18 subjects with 11 intranidal false aneurysms, five flow-related aneurysms, two associated aneurysms and one venous pouch. The location of haemorrhage on the presenting scan significantly correlated with the identified bleeding source using Chi-square analysis (P-value 0.039). Partial targeted embolization was used successfully in 90% with a 9% related technical complication rate not resulting in long-term morbidity or mortality. The mean follow-up period was 34 months with an annual hemorrhage rate of 0.7%. In just under half the patients with AVM bleeding a source of haemorrhage can be identified on DSA and in most cases this will be an intranidal false aneurysm. Flow-related and associated aneurysms in patients with brain AVM can cause haemorrhage and these patients are more likely to have SAH than intracerebral haemorrhage.These weak points are a good target for partial endovascular treatment, are usually accessible and may reduce the higher haemorrhage rate expected over the next two years.
最初表现为脑出血的动静脉畸形(AVM)患者在血管造影上可能有可识别的出血源,这可以成为治疗靶点。先前的研究表明,如果消除薄弱区域,再出血率可能会降低。对在六年期间出现出血性AVM的患者进行了一项回顾性队列研究。通过将CT或MRI上的血肿位置与数字减影血管造影(DSA)上看到的任何血管结构薄弱点相关联,对病例进行回顾以寻找出血源。查阅神经血管内记录以确定治疗靶点。100例患者患有脑AVM,男女比例为1.7:1,41例患者最初表现为出血。在18名受试者中确定了出血源,其中11个为巢内假性动脉瘤,5个血流相关动脉瘤,2个伴发动脉瘤和1个静脉袋。使用卡方分析,首次扫描时的出血位置与确定的出血源显著相关(P值0.039)。90%的患者成功使用了部分靶向栓塞,相关技术并发症发生率为9%,未导致长期发病或死亡。平均随访期为34个月,年出血率为0.7%。在不到一半的AVM出血患者中,可以在DSA上确定出血源,在大多数情况下,这将是巢内假性动脉瘤。脑AVM患者的血流相关和伴发动脉瘤可导致出血,这些患者发生蛛网膜下腔出血(SAH)的可能性高于脑出血。这些薄弱点是部分血管内治疗的良好靶点,通常易于处理,并且可能降低未来两年预期的较高出血率。